

Antibiotics (neonatology)

The initial clinical signs of infection in the newborn tend to be non-specific, however, delays in starting treatment can have serious consequences. Therefore, in case of clinical suspicion of infection, empirical antibiotic therapy should be initiated immediately after collections of samples for culture cultivation. The duration of treatment depends on the clinical response, the type of pathogen and the location of the infection. Combinations of antibiotics are often given to cover a wider range of pathogens, to exploit the synergistic effect and to prevent the development of resistance.

The following groups of antibiotics are most often used in neonatology:

- Beta-lactam antibiotics:
 - narrow-spectrum penicillins: penicillin G, oxacillin;
 - broad-spectrum penicillins: ampicillin, amoxicillin;
 - penicillins with beta-lactamase inhibitors: clavulanic acid (Amoxiclav®, Augmentin®), sulbactam (Unasyn®), tazobactam (Tazocin®);
 - 3rd generation cephalosporins: ceftriaxone, cefotaxime, ceftazidime
 - → gram-negative meningitis, pneumococcal infections, etc.; ceftazidime → pseudomonas infections.
 - carbapenems: meropenem
 - → very broad spectrum (all bacteria except Enterococcus faecium, Burkholderia cepacia, MRSA); parenteral administration only.
- Aminoglycosides: gentamicin, amikacin
 - → gram-negative aerobic bacteria; parenteral administration only; bactericidal.
- Glycopeptides: vancomycin, teicoplanin;
 - → gram-positive bacteria;
- Nitroimidazoles: metronidazole;
 - → anaerobic bacteria;
- Macrolides: azithromycin.

Empirical antibiotic therapy

Early neonatal sepsis

- development of sepsis in the first 48 (72) hours of life;
- most commonly caused by mother-borne bacteria (*Streptococcus agalactiae*, *Escherichia coli*);
- 1st choice antibiotics: penicillin + gentamicin, if *Listeria monocytogenes* is suspected then ampicillin + gentamicin;
- empirical antibiotic therapy should be discontinued after 36-48 hours if the blood culture is negative and the newborn has no clinical signs of infection.

Late neonatal sepsis

- development of sepsis after the first 48 (72) hours of life;
- most often caused by staphylococci (CoNS, *S. aureus*) or enterobacteria;
- 1st choice antibiotics: oxacillin + gentamicin;
- in suspected sepsis with negative blood culture ("clinical sepsis"), are antibiotics usually administered for 5 days;
- in case of positive blood culture, antibiotics are administered for at least 10 days; in the treatment of *S. aureus* for at least 14 days - in consultation with a microbiologist;
- in case of positive cultivation of cerebrospinal fluid or clinical signs of meningitis, the treatment lasts at least 21 days;
- treatment of osteomyelitis, endocarditis or deep abscess takes number of weeks

You can find more detailed information on the page [Neonatal Sepsis](#)

Meningitis

- antibiotics: cefotaxime + amoxicillin or penicillin G ± gentamicin.

You can find more detailed information on the page [Purulent meningitis \(pediatrics\)](#)

Necrotizing enterocolitis

You can find more detailed information on the page [Necrotizing enterocolitis](#)

Urinary tract infections

You can find more detailed information on the page [Urinary tract infections](#)

The most used antibiotics

An overview of beta-lactam antibiotics most commonly used in neonatology:

| Antibiotic | | Intensity and mechanism of action | Spectrum of effect | Side effects | Extra notes |
|---|--|--|--|---|--|
| Penicillin G | basic penicillin | | Gram-positive cocci (except <i>staphylococcus aureus</i>) including all sensitive species of streptococci (not enterococci), Gram-positive bacilli (<i>Clostridium tetani</i> , <i>Corynebacterium diphtheriae</i>), some Gram-negative organisms (<i>Neisseria meningitidis</i> , <i>Haemophilus influenzae</i> , <i>Neisseria gonorrhoeae</i>), <i>E. coli</i> and other Gram-negative organisms are resistant due to their ability to produce beta-lactamase | | poor blood-brain barrier permeability |
| Ampicillin | semi-synthetic penicillinase-sensitive penicillin (aminopenicillin) | bactericidal; inhibits cell wall synthesis | streptococci, pneumococci, enterococci, penicillinase-non-producing <i>staphylococci</i> , <i>Listeria</i> , <i>meningococci</i> , some species of <i>Haemophilus influenzae</i> , <i>Proteus mirabilis</i> , <i>Salmonella</i> , <i>Shigella</i> , <i>E. coli</i> , <i>Enterobacter</i> , <i>Klebsiella</i> | | |
| Oxacillin | semi-synthetic penicillinase-resistant penicillin; antistaphylococcal penicillin | bactericidal | osteomyelitis, septicemia, endocarditis and CNS infections caused by sensitive penicillinase-producing <i>staphylococci</i> | | |
| Flucloxacillin | antistaphylococcal penicillin | | | | |
| Piperacillin/tazobactam (Tazocin) | combination of acylureidopenicillin and a beta-lactamase inhibitor (tazobactam) | | sepsis, intra-abdominal infections, skin, lower respiratory tract and urinary tract infections caused by sensitive beta-lactamase-producing species of <i>St. aureus</i> , <i>H. influenzae</i> , <i>Bacteroides fragilis</i> , <i>Klebsiella</i> , <i>Pseudomonas</i> , <i>Proteus mirabilis</i> , <i>E. coli</i> and <i>Acinetobacter</i> | serum urea and creatinine elevations, interstitial nephritis, renal failure, leukopenia, thrombocytopenia, neutropenia, hemoglobin / hematocrit decline, eosinophilia, AST and ALT elevations, hyperbilirubinemia, cholestatic jaundice, hypokalaemia | good permeability to tissues and body fluids including lungs, intestinal mucosa, interstitial fluid, gallbladder and bile, poor permeability to cerebrospinal fluid without the presence of meningitis |
| Ampicillin/sulbactam (Unasyn) | combination of aminopenicillin and beta-lactamase inhibitor (sulbactam) | bactericidal | beta-lactamase-producing organisms - <i>St. aureus</i> , <i>H. influenzae, <i>E. coli</i>, <i>Klebsiella</i>, <i>Acinetobacter</i>, <i>Enterobacter</i> and anaerobes</i> | | |
| Amoxicillin/clavulanate (Augmentin) | combination of aminopenicillin and beta-lactamase inhibitor (clavulanate) | | | | |
| Cefotaxim | 3rd generation cephalosporin | | | | |
| Ceftazidime | 3rd generation cephalosporin | bactericidal | Gram-negative aerobic bacteria including <i>Neisseria</i> , <i>H. influenzae</i> , some <i>Enterobacteriaceae</i> , <i>Pseudomonas</i> | | synergistic effect with aminoglycosides; good permeability to cerebrospinal fluid |
| | | | pneumococcal and | | |

| | | | |
|------------------|------------|--|--|
| Meropenem | carbapenem | pseudomonas meningitis, Klebsiella pneumoniae ESBL (extended-spectrum beta-lactamase), multidrug-resistant Gram-negative organisms and Gram-positive aerobic and anaerobic pathogens | good permeability to cerebrospinal fluid and most body tissues |
|------------------|------------|--|--|

An overview of non-beta-lactam antibiotics most commonly used in neonatology:

| Antibiotic | | Intensity and mechanism of action | Spectrum of effect | Side effects | Extra notes |
|----------------------|----------------|---|--|--|---|
| Gentamicin | aminoglycoside | bactericidal | Gram-negative aerobic bacteria including Pseudomonas, Proteus, Serratia | | |
| Metronidazole | nitroimidazole | | meningitis, ventriculitis and endocarditis caused by Bacteroides fragilis and other penicillin-resistant anaerobes; severe intra-abdominal infections; colitis caused by Clostridium difficile | | |
| Vancomycin | glycopeptide | bactericidal (bacteriostatic against enterococci) | Gram-positive cocci and bacilli including streptococci, staphylococci (including methicillin-resistant staphylococci, MRSA), clostridia, corynebacteria and Listeria monocytogenes | ototoxicity, nephrotoxicity, thrombophlebitis at the site of administration, allergy (rash, fever) | |
| Rifampicin | rifamycin | bacteriostatic | mycobacteria, Neisseria meningitidis, Gram-positive cocci; elimination of meningococci in symptomatic carriers; prophylaxis of contacts of patients with H. influenzae type B infection; in combination for the treatment of active tuberculosis and staphylococcal infections | anorexia, vomiting, diarrhea, rash, pruritus, eosinophilia, leukopenia, thrombocytopenia, haemolytic anemia, rarely hepatitis, elevated serum urea and uric acid levels, red-orange discoloration of body fluids | good permeability through the blood-brain barrier and into body tissues and fluids, hepatic metabolism, undergoes enterohepatic circulation; it should always be used in combination, as resistance develops rapidly during monotherapy |

Bacterial resistance

More detailed information can be found on the pages *Antibiotic resistance*, *Beta-lactamases*, *Resistance to macrolides and lincosamides (main causes of resistance, efflux)*.

Side effects of antibiotics

References

Related articles

- Neonatal infections
- Antibiotics

External links

- Mechanisms in Medicine: β -Lactams - Mechanisms of Action and Resistance (video) (<https://www.youtube.com/watch?v=qBdYnRhdWcQ>)
- JJ Medicine: Aminoglycosides | Bacterial Targets, Mechanism of Action, Side Effects (video) (<https://www.youtube.com/watch?v=h1d2meyYpOE>)
- Mechanisms in Medicine: Macrolides - Mechanisms of Action and Resistance (video) (<https://www.youtube.com/watch?v=oC21vLFtsjo>)
- Mechanisms in Medicine: The Role of Amphotericin (video) (<https://www.youtube.com/watch?v=H11LP48mbTl>)
- Mechanisms in Medicine: The Role of Azoles (video) (<https://www.youtube.com/watch?v=T-dwE11AhqA>)

Literature

- RENNIE, JM, et al. *Textbook of Neonatology*. 5. vydání. Churchill Livingstone Elsevier, 2012. s. 1025. ISBN

978-0-7020-3479-4.

- GOMELLA, TL, et al. *Neonatology: Management, Procedures, On-Call Problems, Diseases, and Drugs*. 7. vydání. Lange, 2013. s. 944-1001. ISBN 978-0-07-176801-6.